

## Guidance for Industry

### Studies to evaluate the safety of residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI VICH GL-36

#### DRAFT GUIDANCE

*This guidance document is being distributed for comment purposes only*

The objective of this draft guidance is an attempt to address the complexity of the human intestinal flora and reduce uncertainty when determining microbiological ADIs.

Comments and suggestions regarding the document should be submitted to Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>. All comments should be identified with the Docket No. 2003D-0474.

For questions regarding this document, contact Louis T. Mulligan, Center for Veterinary Medicine, (HFV-153), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 301-827-6984, e-mail: [lmulliga@cvm.fda.gov](mailto:lmulliga@cvm.fda.gov).

---

U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Veterinary Medicine  
November 12, 2003

---

2003D-0474

GDL 1

# **STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH A MICROBIOLOGICAL ADI**

Recommended for Consultation  
at Step 4 of the VICH Process  
on 8 May 2003  
by the VICH Steering Committee

THIS GUIDANCE HAS BEEN DEVELOPED BY THE APPROPRIATE VICH EXPERT WORKING GROUP AND IS SUBJECT TO CONSULTATION BY THE PARTIES, IN ACCORDANCE WITH THE VICH PROCESS. AT STEP 7 OF THE PROCESS, THE FINAL DRAFT WILL BE RECOMMENDED FOR ADOPTION TO THE REGULATORY BODIES OF THE EUROPEAN UNION, JAPAN AND USA.

# **Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI**

## **1. INTRODUCTION**

- 1.1. Objectives of the guidance
- 1.2. Background
- 1.3. Scope of the guidance

## **2. GUIDANCE**

- 2.1. Steps in determining the need for a microbiological ADI
- 2.2. Recommendations for determining NOAECs and NOAELs for the endpoints of concern
  - 2.2.1. Disruption of the colonization barrier
    - 2.2.1.1. Detection of colonization barrier disruption
    - 2.2.1.2. Test systems and study design
      - 2.2.1.2.1. *In vitro* tests
      - 2.2.1.2.2. *In vivo* tests
  - 2.2.2. Increase in the population(s) of resistant bacteria in the human colon
    - 2.2.2.1. Detection of changes in the population of resistant bacteria
    - 2.2.2.2. Test systems and study design
      - 2.2.2.2.1. *In vitro* tests
      - 2.2.2.2.2. *In vivo* tests
- 2.3. General recommendations
- 2.4. Derivation of a microbiological ADI
  - 2.4.1. Disruption of the colonization barrier
    - 2.4.1.1. Derivation of an ADI from *in vitro* data
    - 2.4.1.2. Derivation of an ADI from *in vivo* data
  - 2.4.2. Increase in the population(s) of resistant bacteria
    - 2.4.2.1. Derivation of an ADI from *in vitro* data
    - 2.4.2.2. Derivation of an ADI from *in vivo* data

## **3. GLOSSARY**

## **4. REFERENCES**

### **APPENDIX A**

### **APPENDIX B**

## **GENERAL APPROACH TO ESTABLISH A MICROBIOLOGICAL ADI**

This draft guidance, when finalized, will represent the agency's current thinking on safety of residues of veterinary drugs in human food. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statute(s) and/or regulation(s). If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

### **1. INTRODUCTION**

#### **1.1. Objectives of the guidance**

A variety of toxicological evaluations can be performed to establish the safety of veterinary drug residues in human food. An issue that should be addressed for veterinary antimicrobial drugs is the safety of their residues on the human intestinal flora. The objectives of this guidance are (1) to outline the recommended steps in determining the need for establishing a microbiological acceptable daily intake (ADI); (2) to recommend test systems and methods for determining no-observable adverse effect concentrations (NOAECs) and no-observable adverse effect levels (NOAELs) for the endpoints of health concern; and (3) to recommend a procedure to derive a microbiological ADI. It is recognized that different tests may be useful. The experience gained with the recommended tests may result in future modifications to this guidance recommendation.

**FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word "should" in Agency guidances means that something is suggested or recommended, but not required.**

#### **1.2. Background**

The intestinal flora plays an important role in maintaining and protecting the health of individuals. This flora provides important functions to the host such as (1) metabolizing endogenous and exogenous compounds and dietary components; (2) producing compounds that are later absorbed; and (3) protecting against the invasion and colonization by pathogenic microorganisms.

Ingested antimicrobial drugs can potentially alter the ecology of the intestinal flora. They may reach the colon due to incomplete absorption or may be absorbed, circulated and then excreted via bile or secreted through the intestinal mucosa.

**It is recommended that the microbiological endpoints of current public health concern that should be considered when establishing a microbiological ADI are:**

Disruption of the colonization barrier: The colonization barrier is a function of the normal intestinal flora that limits colonization of the colon by exogenous microorganisms, as well

## ***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

as overgrowth of indigenous, potentially pathogenic microorganisms. The capacity of some antimicrobial drugs to disrupt this barrier is well established and known to have human health consequences.

Increase of the population(s) of resistant bacteria: For the purposes of this guidance, resistance is defined as the increase of the population(s) of bacteria in the intestinal tract that is (are) insensitive to the test drug or other antimicrobial drugs. This effect may be due either to the acquisition of resistance by organisms which were previously sensitive or to a relative increase in the proportion of organisms that are already less sensitive to the drug.

An extensive literature review did not reveal reports on human health effects (e.g. prolonged antimicrobial therapy, prolonged hospital stay, predisposition to infection, treatment failure, etc.) that occur as a result of changes in the proportion of antimicrobial resistant bacteria in the normal human intestinal flora. Although information is not available, we believe that such effects are likely, based on our understanding of microbial ecology and its role in human health.

Although the effect of antimicrobial residues in food on the human intestinal flora has been a concern for many years, a harmonized approach to determine the threshold dose that might adversely disturb the flora has not been established. International regulatory bodies have used a formula-based approach for determining microbiological ADIs for antimicrobial drugs based on minimum inhibitory concentration (MIC) data against human intestinal bacteria. Due to the complexity of the intestinal flora, uncertainty factors have been traditionally included in the formula. However, the use of uncertainty factors results in conservative estimates and it is recommended that more relevant test systems should be developed that allow a more realistic estimate of a microbiological ADI.

The present guidance is an attempt to address the complexity of the human intestinal flora and reduce uncertainty when determining microbiological ADIs. The guidance recommends a process for determining if a microbiological ADI is appropriate and discusses test systems that take into account the complexity of the human intestinal flora. These test systems could be used for addressing the effects of antimicrobial drug residues on human intestinal flora for regulatory purposes.

**Since further research is needed to confirm the reliability and validity of all test systems discussed in this guidance (see Appendix A), this guidance does not recommend any one particular system for use in regulatory decision-making. Instead, this guidance provides recommendations for a harmonized approach to establish a microbiological ADI and offers test options rather than specifying a testing regimen.**

### **1.3. Scope of the guidance**

This document provides guidance for assessing the human food safety of residues from veterinary antimicrobial drugs with regard to effects on the human intestinal flora. However, it does not limit the choice of studies that may be performed to establish the safety of residues in human food with respect to adverse effects on human intestinal flora. This guidance does not

## ***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

preclude the possibility of alternative approaches that may offer an equivalent assurance of safety, including scientifically based reasons as to why microbiological testing may not be appropriate.

## **2. GUIDANCE**

Testing of drugs with antimicrobial activity for use in food-producing animals addresses the safety of their residues. If no microbiologically active residue reaches the human colon, the ADI may be derived using data from standard toxicology tests.

### **2.1. Steps in determining the need for a microbiological ADI**

When determining the need for a microbiological ADI, the following sequence of steps is recommended. The data may be obtained experimentally, from the published literature, or other sources.

**Step 1.** Are residues of the drug, and (or) its metabolites, microbiologically active against representatives of the human intestinal flora?

- Recommended data:
  - MIC data from the following relevant genera of intestinal bacteria (*E. coli*, and species of *Bacteroides*, *Bifidobacterium*, *Clostridium*, *Enterococcus*, *Eubacterium* (*Collinsella*), *Fusobacterium*, *Lactobacillus*, *Peptostreptococcus/Peptococcus*).
  - It is recognized that the understanding of the relative importance of these microorganisms is incomplete and that the taxonomic status of these organisms can change. The selection of organisms should take into account current scientific knowledge.
- If no information is available, it is recommended that you assume that the compound and (or) its metabolites are microbiologically active.

**Step 2.** Do residues enter the human colon?

- Recommended data:
  - Absorption, distribution, metabolism, excretion (ADME), bioavailability, or similar data may provide information on the percentage of the ingested residue that enters the colon.
- If no information is available in humans, it is recommended that you use appropriate animal data. If there is no available information, it is recommended that you assume that 100% of the ingested residue enters the colon.

**Step 3.** Do the residues entering the human colon remain microbiologically active?

- Recommended data:
  - Data demonstrating loss of microbiological activity from *in vitro* inactivation studies of the drug incubated with feces or data from *in vivo* studies evaluating the drug's microbiological activity in feces or colon content of animals.

## ***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

**If the answer to any of questions in steps 1, 2, or 3 is “no”, then the ADI is not recommended to be based on microbiological endpoints and the remaining steps should not be addressed.**

**Step 4.** Is there any scientific justification to eliminate the need for testing either one or both endpoints of concern? It is recommended that available information regarding colonization barrier disruption and resistance emergence for the drug be considered. If a decision cannot be made based on the available information, both endpoints should be examined.

**Step 5.** Determine the NOAECs/NOAELs for the endpoint(s) of concern as established in step 4. The most appropriate NOAEC/NOAEL should be used to determine the microbiological ADI.

## **2.2. Recommendations for determining NOAECs and NOAELs for the endpoints of concern**

### **2.2.1. Disruption of the colonization barrier**

#### **2.2.1.1. Detection of colonization barrier disruption**

Changes in bacterial populations are indirect indicators of potential disruption of the colonization barrier. These changes can be monitored by various enumeration techniques in a variety of test systems. A more direct indicator of barrier disruption is the colonization or overgrowth of an intestinal ecosystem by a pathogen. *In vivo* test systems or complex *in vitro* test systems (e.g. fed-batch, continuous, or semi-continuous culture systems) have the potential to evaluate barrier disruption as evidenced by colonization of a challenge organism added to the test system.

Challenge organisms (e.g. *Salmonella*, *Clostridium*) should be insensitive to the test drug. Inoculation schemes with the challenge organisms should take into account the timing of the challenge relative to drug treatment, the number of organisms per challenge dose, and the number of times that the test system is challenged.

#### **2.2.1.2. Test systems and study design**

##### **2.2.1.2.1. *In vitro* tests**

The use of MICs to assess the potential for a drug to disrupt the colonization barrier does not take into account the complexity of the human intestinal flora. Therefore, the MIC<sub>50</sub> of the most relevant genus/genera for which the drug is active (see Section 2.1.) results in a conservative estimate of a NOAEC for disruption of the colonization barrier. The NOAEC estimate is conservative because, among other reasons, the inoculum density is orders of magnitude lower than the bacterial population in the intestinal tract<sup>1</sup>. Therefore, the NOAEL may be considered as an option to establish an ADI. It is recommended that the isolates be obtained from multiple healthy individuals, and should include a minimum of 10 isolates from each of the genera listed in Section 2.1.

Each MIC test of a pure culture of a relevant isolate provides data for a single species. Other *in vitro* test systems provide information for hundreds of bacterial species (>10<sup>8</sup> bacterial cells/g) for each fecal inoculum. Each inoculum can be tested in replicate to determine treatment

### **Contains Non-Binding Recommendations**

*Draft—Not for Implementation*

effects. Based on all the above, *in vitro* systems using fecal batch cultures are inherently more robust and relevant than the MIC test system.

Other test systems discussed below, which model the intestinal flora, may result in a more appropriate NOAEC and possibly a higher ADI.

Fecal slurries provide a simple test system to derive a NOAEC for disruption of the colonization barrier following short-term exposure to the drug and may be appropriate for dose-titration studies. Individual fecal samples, when diluted 1:1 in anaerobic buffer and incubated for short time periods, can be monitored for changes in bacterial populations and the production of short chain fatty acids. These two parameters, when monitored together, can be used as indirect indicators of barrier disruption. Changes in bacterial populations take place over time. For some test compounds it is likely that effects will be observed over a very short time period, e.g. 4 hours (depending on which part of the complex fecal flora is being affected) whereas for other compounds the time taken before a change in population can be determined will be greater. The different components of the complex fecal flora do not all have the same growth rate and so it is recommended that sufficient time is allowed for effects to be determined. The nature of the test antimicrobial is also significant in this regard as different classes of compounds have different modes of action and are active against different components of the bacterial population. It is therefore recommended that a sufficient time frame is provided to determine any impact upon the flora. A number of fecal donors (normally 5 of each gender) can be sampled to better account for inter-individual variation. The NOAEC derived from this test system may prove to be a conservative estimate of barrier disruption.

Semi-continuous, continuous and fed-batch cultures of fecal inocula may be appropriate to evaluate disruption of the colonization barrier following prolonged exposure to the drug. However, exploratory work using continuous and semi-continuous cultures has given various NOAECs for barrier disruption because of differences in protocols. In addition, there are unresolved issues such as the impact of fecal inoculum, dilution rate, duration of drug exposure on the observed NOAEC, and reproducibility of the tests. As a consequence, it is recommended that study designs take into account the issues raised in Appendix A.

#### **2.2.1.2.2. *In vivo* tests**

*In vivo* test systems using human flora-associated (HFA) and conventional laboratory animals may be suitable for the assessment of disruption of the colonization barrier. Compared to conventional laboratory animals, the intestinal flora of HFA animals possesses greater similarity to the human intestinal flora, both in terms of the range of bacterial populations and metabolic activity. However, the intestinal flora derived from humans may not be stable in the HFA animals. The relative importance of the stability of the implanted flora and the specific composition of the flora is unknown. For technical reasons, the conventional laboratory animal can be tested in higher numbers, which allows a more robust statistical analysis of the results.

It is recommended that study design take into account factors such as animal species, gender, variability of donor inocula, number of animals per group, diet, randomization of treatment groups, minimization/elimination of coprophagy, housing of animals within an isolator, cross contamination within the isolator and route of drug administration (e.g. gavage, drinking water). It is recommended that germ-free animals be inoculated in sequence, first with a *Bacteroides fragilis* strain, followed by the fecal inoculum.



## **2.2.2. Increase in the population(s) of resistant bacteria in the human colon (as defined in Section 1.2.)**

### **2.2.2.1. Detection of changes in the population of resistant bacteria**

It is recommended that studies to evaluate resistance emergence take into account the organisms of concern in the intestinal tract and the documented resistance mechanisms to the drug class. Preliminary information regarding the prevalence of resistance in the human intestinal flora, such as daily variation within individuals and the variation among individuals can be useful in developing criteria for evaluating resistance emergence. MIC distributions of sensitive and known resistant organisms of concern can provide a basis to determine what drug concentration should be used in the selective agar media to enumerate resistant organisms in the fecal samples. Since drug activity against an organism can vary with test conditions, the MIC of the organism growing on selective medium should be compared to the MIC determined by standard methods where available (e.g., National Committee for Clinical Laboratory Standards [NCCLS]<sup>2</sup>). Changes in the proportions of resistant organisms during pre-treatment, treatment and post-treatment periods can be evaluated by enumeration techniques on media with and without the antimicrobial drug, applying phenotypic and molecular methodologies.

Changes in antimicrobial resistance can be influenced by factors other than drug exposure (e.g. animal stress) which should be taken into consideration in animal test systems.

### **2.2.2.2. Test systems and study design**

#### **2.2.2.2.1. *In vitro* tests**

The duration of exposure required for resistance to develop in a population of bacteria can be dependent on the drug, the nature of the resistance mechanisms, and how it evolves in nature (e.g. via gene transfer between cells, by gene mutations). For these reasons acute studies of pure cultures to assess the endpoint are not recommended. Therefore, MIC tests should not be used to determine a NOAEC for increases in resistant populations.

Defined cultures may provide useful information to determine the potential for a resistant population to emerge due to mutation in an isolate and/or gene transfer among isolates. However, these test systems are not designed to evaluate changes in resistant populations and are not recommended.

Tests systems using short-term exposure of fecal slurries to a drug are not recommended for resistance emergence testing because the duration of the test is inadequate to assess changes in resistant populations.

Continuous and semi-continuous cultures and fed-batch cultures of fecal inocula provide a means to evaluate long-term exposure of bacteria to the drug. Refer to Appendix A for issues that are recommended to be addressed regarding study conduct and data evaluation.

#### **2.2.2.2.2. *In vivo* tests**

Changes in resistant populations can be assessed in HFA-rodents. General study design and supporting protocol should follow the recommendations stated in 2.2.1.2.2. The test system

**Contains Non-Binding Recommendations**  
*Draft—Not for Implementation*

supports a complex flora, and would be a source of genetic resistance determinants. The system accommodates more replication than the continuous or semi-continuous culture systems, but less than fed-batch cultures. The variability of the HFA-rodent test has not been assessed; however it is useful for identifying gender differences. There are also advantages to conducting resistance studies in conventional laboratory animals.

HFA-rodents and conventional animals provide means to evaluate the potential for resistance emergence following long-term exposure of bacteria to the drug. Refer to Appendix A for issues that are recommended to be addressed for study conduct and data evaluation.

### **2.3. General recommendations**

- It is recommended that fecal samples or bacterial isolates from human donors be obtained from healthy subjects with no known exposure to antimicrobials for at least 3 months.
- In the case of *in vivo* tests, it is recommended that the test species selected for testing allow for (1) maximum independent replication; (2) evaluation of both genders; (3) sufficient quantity of feces to be collected for analyses; and (4) minimal coprophagy.
- Statistical issues should be addressed when designing studies of antimicrobial residues because they differ significantly from those applicable to general toxicity testing (See Appendix B).
- It is recommended that the pre-validation and validation process, such as that being developed by OECD since 1996<sup>3</sup>, be considered for subsequent validation of test systems to assess the effects of antimicrobial drugs on human intestinal flora. The process should be adapted and modified for this use depending on the test system being validated.

### **2.4. Derivation of a microbiological ADI**

When more than one value can be determined for the microbiological ADI, in accordance with the methods discussed below, the most appropriate value (relevant to humans) should be used.

#### **2.4.1. Disruption of the colonization barrier**

##### **2.4.1.1. Derivation of an ADI from *in vitro* data**

If the endpoint of concern is disruption of the colonization barrier, ADIs may be derived from MIC data, fecal slurries, semi-continuous, continuous, and fed-batch culture test systems.

ADI derived from MIC data:

$$\text{ADI} = \frac{\text{MIC}_{\text{calc}} \times \text{Mass of Colon Content (220 g/day)}}{\text{Fraction of oral dose available to microorganisms} \times 60 \text{ kg person}}$$

## ***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

$MIC_{calc}$ : The lower one-tailed 10% confidence limit of the mean  $MIC_{50}$  of the most relevant genera for which the drug is active (minimum 10 isolates/genus). The  $MIC_{50}(s)$  of the genus (genera) where most/all strains or isolates show inherent resistance to the drug should not be included in the determination. See list in section 2.1. for relevant genera. This approach is recommended although it is recognized that the  $MIC_{50}$  among different genera of bacteria is not necessarily normally distributed.

ADI derived from other *in vitro* test systems:

$$ADI = \frac{NOAEC}{\text{Fraction of oral dose available to microorganisms}} \times \frac{\text{Mass of Colon Content (220 g/day)}}{60 \text{ kg person}}$$

**NOAEC:** It is recommended that the lower one-tailed 10% confidence limit of the mean NOAEC from these systems should be used to account for the variability of the data. Therefore, in this formula uncertainty factors are not generally needed to determine the microbiological ADI.

### Mass of colon content:

The 220 g value is based on the colon content measured from accident victims.

### Fraction of an oral dose available for microorganisms:

It is recommended that the fraction of an oral dose available for colonic microorganisms be based on *in vivo* measurements for the drug administered orally. Alternatively, if sufficient data are available, the fraction of the dose available for colonic microorganisms can be calculated as 1 minus the fraction (of an oral dose) excreted in urine. Human data are preferred, but data in more than one animal species are acceptable. In the absence of data to the contrary, it should be assumed that metabolites have antimicrobial activity equal to the parent compound. The fraction may be lowered if the applicant provides quantitative *in vitro* or *in vivo* data to show that the drug is inactivated during transit through the intestine.

#### 2.4.1.2. Derivation of an ADI from *in vivo* data

The microbiological ADI is the NOAEL divided by the uncertainty factor.

Uncertainty factors for *in vivo* studies should be assigned as appropriate, taking into consideration the class of compound, the protocol, numbers of donors, and sensitivity of the measured outcome variables.

#### **2.4.2. Increase in the population(s) of resistant bacteria**

##### 2.4.2.1. Derivation of an ADI from *in vitro* data

If the endpoint of concern is an increase in the population(s) of resistant bacteria, NOAECs derived from semi-continuous, continuous, and fed-batch culture test systems may be used to establish a microbiological ADI.

$$ADI = \frac{NOAEC}{\text{Fraction of oral dose}} \times \frac{\text{Mass of Colon Content (220 g/day)}}{60 \text{ kg person}}$$

**Contains Non-Binding Recommendations**  
*Draft—Not for Implementation*

available to  
microorganisms

NOAEC: It is recommended that the lower one-tailed 10% confidence limit of the mean NOAEC from these systems be used to account for the variability of the data. Therefore, in this formula uncertainty factors are not generally needed to determine the microbiological ADI. However, where there are concerns arising from inadequacies in the quality or quantity of *in vitro* data used in determining the NOAEC, the incorporation of an uncertainty factor may be warranted.

#### 2.4.2.2. Derivation of an ADI from *in vivo* data

The microbiological ADI is the NOAEL divided by the uncertainty factor.

Uncertainty factors for *in vivo* studies should be assigned as appropriate, taking into consideration the class of compound, the protocol, numbers of donors, and sensitivity of the measured outcome variables.

### **3. GLOSSARY**

The glossary includes terminology referred to in the Appendices as well as in the text.

Acceptable Daily Intake (ADI)	An estimate of the amount of a substance, expressed on a body weight basis, that can be ingested daily over a lifetime without appreciable risk to human health.
Antimicrobial Activity	The effect of an antimicrobial on a bacterial population.
Antimicrobial	A drug substance that is either biologically derived or chemically produced with antimicrobial activity as its major effect.
Balanced Design	A statistical design is balanced if each combination of values or levels of all factors in the design (treatment factors, factors of interest such as gender, or blocking factors) have the same number of experimental units or replicates. A partially balanced design is not balanced, but combinations of treatments and other factors occur in a regular way such that the analysis remains relatively simple.
Batch Culture	A culture where neither substrate nor waste products are removed until completion of incubation, normally incubated for short periods, generally up to 24 hours.
Blocking Factor	An experimental factor whose values or levels define groups of experimental units that are similar or that can be expected to respond in a similar manner. Systematic variation among blocks can be removed from the estimate of error in the statistical analysis, resulting in greater precision. An example is a cage containing several animals, which are the experimental units, or an isolator containing several cages.
Challenge organism	An organism added experimentally to a test system to evaluate colonization barrier disruption.
Colonization	The establishment of microorganisms in the intestinal tract.
Colonization Barrier	A function of the normal intestinal flora that limits colonization of the colon by exogenous microorganisms, as well as overgrowth of indigenous, potentially pathogenic microorganisms.

***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

Complete Design	A statistical design is complete if all combinations of factors or groups in the design have at least one observation. An incomplete design is one in which no observations are made for some combinations of factors.
Continuous Culture	A culture maintaining continuous growth of microorganisms by the simultaneous supply of nutrient and removal of spent medium, maintaining a constant microbial load within a fixed incubation volume.
Conventional Laboratory Animal	A laboratory animal with its natural indigenous intestinal flora.
Coprophagy	The ingestion of feces.
Defined Culture	A microbial culture in which all microbial species are known.
Dilution (Flow) Rate	The rate of supply and removal of medium from a continuous culture system. Dilution rate controls the microbial growth rate within a continuous culture system.
Donor (Fecal) Inocula	Fecal flora obtained from human volunteers and used to inoculate the test system. It is considered to be equivalent to the intestinal flora.
Drug Residue	The drug, including all derivatives, metabolites and degradation products that persists in or on food.
Experimental Unit	The standard amount of experimental material to which a treatment is applied and a measurement is made. Examples include a whole animal or a specific organ or tissue, a cage containing several animals, a cell culture or an individual chemostat.
Factorial Design	An experimental design that involves combinations of a number of factors, including a treatment factor, each having two or more values or levels. Other factors may include stratification (e.g. gender) or blocking factors (e.g. cage). Typically the outcome variable is measured on a number of experimental units at each combination of levels of the various factors. The statistical analysis of the data involves a multifactorial analysis of variance.
Fecal Slurry	Diluted human feces or fecal solids.
Fed-Batch Culture	A batch culture fed continuously or semi-continuously with nutrient medium. Portions of the fed batch culture can be withdrawn at pre-determined intervals. A constant culture volume is not maintained.
Human Flora-Associated	A germ-free host animal implanted with human fecal flora.

**Contains Non-Binding Recommendations**

*Draft—Not for Implementation*

(HFA) Animal

Interaction Effect	Treatment effects that are modified by the presence of other factors. For example, the effect of a treatment may be greater or less in males than females, or may change over time.
Intestinal Flora	The normal microbial flora of the colon.
Minimum Inhibitory Concentration (MIC)	The lowest concentration of an antimicrobial compound that inhibits growth of the test organism as determined by standardized test procedures.
MIC <sub>50</sub>	The concentration of an antimicrobial compound at which 50% of the tested isolates within a relevant genus are inhibited.
Microbiological ADI	An ADI established on the basis of microbiological data.
No-Observable Adverse Effect Concentration (NOAEC)	The highest concentration that was not observed to cause any adverse effect in a particular study.
No-Observable Adverse Effect Level (NOAEL)	The highest administered dose that was not observed to cause any adverse effect in a particular study.
Outcome Variable	A specific parameter measured in an experiment and defined as part of the protocol, and are the measurements actually made in the study.
Semi-continuous Culture	A culture where substrate and/or waste products are added and/or removed in a semi-continuous manner maintaining a fixed incubation volume.
Short Chain Fatty Acid	The volatile fatty acids containing 2 to 6 carbon atoms that are produced by the intestinal flora. The principal acids are acetic, propionic and butyric.
Solid Phase	The particulate matter in an <i>in vitro</i> test system.

***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

Systematic Variation	Factors that affect outcome variables. Such variation is systematic in the sense that it represents an effect that is reliably present. Systematic variation is distinguished from random variation, which is not predictable. Systematic variation may be caused by factors that are of interest, such as gender, or by factors such as the particular isolator, which are not.
Test System	A method used to determine the effects of antimicrobial residues on the human intestinal flora.

#### **4. REFERENCES**

1. Cerniglia, C.E., and Kotarski, S. 1999. Evaluation of Veterinary Drug Residues in Food for Their Potential to Affect Human Intestinal Microflora. *Regulatory Toxicology and Pharmacology*. **29**, 238-261.
2. National Committee for Clinical Laboratory Standards (NCCLS). 2000. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Fifth Edition. NCCLS document M11-A5. NCCLS 940 West Valley Road, Suite 1400, Wayne, PA, USA.
3. OECD. 2001. Series of Testing and Assessment No. 34, Environment, Health and Safety Publications. Draft Guidance Document on the Development, Validation and Regulatory Acceptance of New and Updated Internationally Acceptable Test Methods and Hazard Assessment. Organization for Economic Cooperation & Development, Paris.



## **APPENDIX A**

### **Issues that should be Investigated in Developing Test Systems**

#### **1. Experimental Conditions**

Data generated for continuous flow, semi-continuous flow and fed-batch studies will be affected by the growth conditions (e.g., growth medium, pH, dilution rate). Different bacterial species may have different growth rates under the experimental conditions used for the test system. If the dilution rate of the culture exceeds the growth rate of a bacterial species, then this species ultimately will be eliminated from the test culture. The test system should be designed to maximize the retention of the different bacteria, and maintain the complexity of the initial inoculum.

Test antimicrobials can affect growth rates of various bacterial groups. This may lead to loss of components of the mixed culture by a reduction of growth rate below that of the dilution rate used in the test system, which might cause some components of the flora to be washed out of the culture. This may be minimized by developing test conditions with lower dilution rates.

Antimicrobial susceptibility is influenced by the physical condition of the exposed organisms, which will be influenced by the growth conditions used in the test system. Based on the above, further work is needed to determine the impact of different growth conditions on the NOAECs derived for colonization barrier disruption and the increase in the population of resistant bacteria.

A number of factors should be considered in protocols for *in vivo* test systems. Cross-contamination is a major issue when performing animal studies within a germ-free isolator. The protocol should be designed to minimize cross-contamination.

#### **2. Inoculum**

The composition of the intestinal flora may vary among individuals with respect to bacterial groups and resistant organisms. The bacterial populations are relatively stable within a single individual, but this is not necessarily the case for resistant bacterial groups.

It is preferred that data to determine the effect of antimicrobial residues on the intestinal flora be derived from test systems that use fecal inocula obtained from individual donors. It is recommended that multiple donors be used to account for differences in flora between individuals. Pooled inocula do not account for differences in flora between individuals. The composition of the donor inocula should be taken into account when interpreting study results.

The effect of freezing on the stability and composition of the fecal inocula is not well understood and should be investigated.

#### **3. Study duration**

The optimum incubation time to monitor for changes in bacterial populations in fecal batch cultures needs to be determined. Likewise, in the case of complex long-term *in vitro* or *in vivo*

***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

test systems, the period during which the integrity and complexity of the intestinal flora remains stable and representative of the intestinal flora needs to be determined.

## **APPENDIX B**

### **Statistical Issues to be Considered When Designing Studies of Antimicrobial Residues**

Two broad endpoints of current public health concern were identified: 1) disruption of the colonization barrier and; 2) increases in population(s) of resistant bacteria. The experimental design should depend on which of these is to be addressed and should take account of the particular outcome variables. It is recommended that a design paradigm for these test systems involve choice of the test system, application of treatments and follow-up of the system over time. The choice of test system depends on the characteristics of the human intestinal tract that is represented by the test system. Since the MIC tests are simple in design, many of the issues discussed below do not apply to this method.

A central component of the design is the definition of the experimental unit. For an *in vivo* test system, for example, the unit may be an individual animal or an entire cage. If cages are grouped within isolators, some or all of the treatments to different cages within each isolator can be applied. In this case the isolator becomes a blocking factor, since cages within the same isolator would be expected to respond in a similar fashion. The use of blocking factors is an important tool for reducing systematic variation. A related question is whether there are other systematic factors such as gender that should be included, that is, whether a factorial design should be used. If there are multiple factors, then the design involves choices of what combinations of these should be included. It is important that this be done in such a way that the resulting design is balanced. In a complete, balanced design, all combinations are represented, and occurs the same number of times. It is also possible to have incomplete designs, as well as various kinds of partial balance. For such designs the analysis of variance is recommended, and such designs can be useful when, for example, experimental resources are limited. An example of an incomplete design is the standard two period cross-over design.

It should be decided how the treatments are applied to the experimental units. In some cases a two-stage treatment, involving a drug treatment and a bacterial challenge, may be necessary. It is recommended that there are at least three antimicrobial treatment groups in addition to appropriate control groups. The choice of antimicrobial treatment levels depends on the desired range of doses, but should cover both effect and no-effect levels. The duration and the method of drug administration depends on the test system. An important aspect of some studies is the evolution of effects over time, and repeated measurement of outcome variables are recommended. Common issues are the timing and spacing of the measurements and bias caused by missing data.

Control of random variation due to biological variability and to measurement error depends on the number of experimental units and number of samples. This number can be determined from previous knowledge of the test system and outcome variables, either from past experience or through a sample size computation, which should be employed where possible. Sufficient replication should be included to allow precise measurement of treatment effects and appropriate interaction effects, e.g., treatment effects that change over time. In some studies, it may be important to examine such interaction effects as part of the statistical analysis. Another type of replication is the pooling of fecal samples from animals in a single cage or the pooling of

***Contains Non-Binding Recommendations***

*Draft—Not for Implementation*

fecal samples from different donors. In both cases, we have the benefits of averaging, but not the ability to estimate variability among replicates. Pooling may obscure individual effects (of treatment and/or inoculum), and thus its use should be considered in terms of study objectives.